Answers are grounded in this paper and cite their sources.
Highlights the economic impact of pharmaceutical marketing in driving the shift from inexpensive older antihypertensives to costly newer agents.
THE COST of treating hypertension in the United States exceeds $10 billion per year,¹most of which is spent on medications. Prescription drug costs are rising at three times the general inflation rate and are the largest out-of-pocket medical expense for three fourths of all elderly patients.²An important cause of rising drug costs is a shift in physician prescribing from inexpensive old drugs to expensive new drugs,³which is driven to a considerable extent by new drug marketing. This sometimes includes active discouragement of the use of older drugs, as with diuretics,⁴but often lack of promotion alone is sufficient to cause an older drug to fall into disuse.⁵Inexpensive generic drugs are not advertised and are less likely to be discussed in symposia or by visiting lecturers or studied and reported on in industry-funded trials. Negative reports about these drugs go unchallenged, positive
No takes yet. Share an insight, caveat, or question.
Frank A. Lederle (1993) conducted an editorial in Hypertension. Inexpensive generic drugs vs. Expensive new drugs was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: